Clinical applications of induced pluripotent stem cell-mediated therapies in cancer: progress, challenges, and future directions.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical translation challenges without primary data or systematic search methodology.
PubMed 41728817 · doi:10.1080/17460751.2026.2629846
What was done
This narrative review summarizes the development and clinical translation of induced pluripotent stem cell (iPSC)-derived therapies for hematological malignancies, specifically focusing on off-the-shelf CAR-T and CAR-NK cells and bone marrow reconstitution following chemotherapy or radiation.
What was found
The abstract reports no numerical findings, quantitative metrics, or specific study counts. It qualitatively notes that iPSC-derived immune cells demonstrate specificity, persistence, and cytotoxicity against leukemia and lymphoma, while identifying major translational hurdles including teratoma risk, manufacturing complexity, and cost.
Why it matters
iPSC technology has the potential to provide scalable, standardized cell immunotherapies that circumvent the donor limitations and delays inherent to autologous cell therapies. Achieving widespread clinical utility will depend on resolving critical safety and manufacturing constraints.
Limits
The paper is an unstructured narrative review containing no primary clinical trial data or systematic synthesis. The abstract provides no quantitative measures of efficacy, safety, or persistence, and clinical feasibility remains constrained by unresolved safety risks such as teratoma formation.
Cited by
- supports Induced pluripotent stem cells (iPSCs) can be differentiated into functional T cells.